Baker Tilly’s outlook on what lies ahead for industry leaders

Join Baker Tilly for a mid-year check-in on the life sciences industry with our leaders, where we will reflect on key developments from the first half of the year and assess the trends shaping the remainder of 2025 and beyond, such as:

• Strategic response: Navigating the ripple effects of NIH funding shifts, tariff uncertainty, reduced FCPA enforcement, and evolving global compliance expectations as the administration’s policies reshape the industry landscape.
• Capital markets: The state of funding for emerging companies and the realities of scaling in a competitive environment
• Regulatory outlook: Updates on drug pricing transparency, gross-to-net dynamics and policy shifts tied to election-year agendas
• HCP engagement: Why simplification, standardization and compliance are more critical than ever
• Technology and risk: Leveraging tech to manage regulatory exposure and streamline operations
• Evidence generation: Demonstrating value throughout the product lifecycle to align with payer expectations

This mid-year session is designed to equip life sciences leaders with timely insights, actionable takeaways and the strategic foresight needed to adapt and thrive in a highly dynamic environment.

Who should attend?

C-Suite professionals, presidents, vice presidents, management and other leaders of life sciences organizations